Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.27
-0.4%
$20.45
$13.30
$30.03
$1.21B0.93419,198 shs589,226 shs
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$7.74
-6.5%
$7.58
$6.11
$19.00
$797.47M1.889,665 shs76,302 shs
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
$1.51
-2.3%
$1.77
$0.89
$21.95
$11.19M2.22152,830 shs74,891 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$16.49
-1.4%
$16.29
$10.91
$40.26
$1.01B2.82466,120 shs351,933 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-0.44%-2.78%+4.92%+13.62%-9.51%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
-6.52%-5.38%+6.46%-14.95%-41.27%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-2.27%-8.48%-1.31%+16.15%-89.77%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-1.38%-5.12%-4.63%+8.13%-41.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.6617 of 5 stars
3.52.00.00.02.24.20.0
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
1.3204 of 5 stars
3.51.00.00.02.60.00.0
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1.0341 of 5 stars
0.05.00.00.02.70.00.6
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.0293 of 5 stars
3.62.00.00.03.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$41.20103.26% Upside
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
3.00
Buy$18.00132.56% Upside
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.00
N/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.29
Buy$53.40223.83% Upside

Current Analyst Ratings Breakdown

Latest MBIO, SYRE, ELVN, and GYRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/26/2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$18.00
8/6/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$65.00
7/2/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $48.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.00
6/16/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$37.00
(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$8.25 per shareN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$105.76M7.05$0.18 per share41.92$1.34 per share5.78
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/A$0.40 per shareN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K1,119.10N/AN/A$4.97 per share3.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$12.09M$0.01774.77N/A4.08%7.67%6.19%11/12/2025 (Estimated)
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
-$15.75M-$78.00N/AN/AN/AN/AN/A-29.49%11/6/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$208.02M-$3.40N/AN/AN/AN/A-71.30%-38.69%11/6/2025 (Estimated)

Latest MBIO, SYRE, ELVN, and GYRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.49+$0.04-$0.49N/AN/A
8/11/2025Q2 2025
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
$0.03$0.02-$0.01$0.04$30.80 million$26.77 million
8/8/2025Q2 2025
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A-$0.19N/A-$0.19N/AN/A
8/5/2025Q2 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.73-$0.49+$0.24-$0.49N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/AN/AN/AN/AN/A
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
32.58
32.58
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
N/A
5.40
4.87
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
N/A
1.30
1.30
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
6.49
6.49

Institutional Ownership

CompanyInstitutional Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
23.99%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
9.95%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%

Insider Ownership

CompanyInsider Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
25.90%
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
10.00%
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
0.21%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.43%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5059.24 million43.89 millionOptionable
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
4096.31 million86.68 millionNo Data
Mustang Bio, Inc. stock logo
MBIO
Mustang Bio
1007.24 million7.23 millionNot Optionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7360.40 million51.08 millionOptionable

Recent News About These Companies

Spyre Therapeutics Announces Grants of Inducement Awards

New MarketBeat Followers Over Time

Media Sentiment Over Time

Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$20.27 -0.09 (-0.44%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$20.27 0.00 (0.00%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Gyre Therapeutics stock logo

Gyre Therapeutics NASDAQ:GYRE

$7.74 -0.54 (-6.52%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$8.04 +0.30 (+3.81%)
As of 08/29/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

Mustang Bio stock logo

Mustang Bio NASDAQ:MBIO

$1.51 -0.04 (-2.27%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$1.53 +0.02 (+1.32%)
As of 08/29/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$16.49 -0.23 (-1.38%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$16.48 0.00 (-0.03%)
As of 08/29/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.